A Phase 2 Study of the MET Kinase Inhibitor INC280 in Papillary Renal Cell Cancer

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 24, 2014

Primary Completion Date

December 17, 2021

Study Completion Date

December 17, 2021

Conditions

Kidney Cancer

Interventions

DRUG

INC280

Supplied by Novartis as film-coated tablet for oral use.

Trial Locations (1)

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda

All Listed Sponsors

lead

National Cancer Institute (NCI)

NIH

NCT02019693 - A Phase 2 Study of the MET Kinase Inhibitor INC280 in Papillary Renal Cell Cancer | Biotech Hunter | Biotech Hunter